Avalon GloboCare Corp 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-38728 AVALON GLOBOCARE CORP.(Exact name of registrant as specified in its charter) Not Applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on whichregistered The Nasdaq Capital Market Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act. (Check one): Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ As of May 11, 2026, 12,047,651 shares of common stock, $0.0001 par value per share, were outstanding. AVALON GLOBOCARE CORP. FORM10-Q For the Quarterly Period Ended March 31, 2026 Table of Contents PagePart I – Financial InformationItem 1. Financial Statements1Condensed Consolidated Balance Sheets – At March 31, 2026 (Unaudited) and December 31, 20251Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) – For the Three MonthsEnded March 31, 2026 and 20252Condensed Consolidated Statements of Changes in Equity (Deficit) (Unaudited) — For the Three Months EndedMarch 31, 2026 and 20253Condensed Consolidated Statements of Cash Flows (Unaudited) – For the Three Months Ended March 31, 2026 and20255Notes to Unaudited Condensed Consolidated Financial Statements6Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations29Item 3. Quantitative and Qualitative Disclosures About Market Risk36Item 4. Controls and Procedures36Part II – Other InformationItem 1. Legal Proceedings37Item 1A. Risk Factors37Item 2. Unregistered Sales of Equity Securities and Use of Proceeds37Item 3. Defaults Upon Senior Securities38Item 4. Mine Safety Disclosures38Item 5. Other Information38Item 6. Exhibits39Exhibit Index39Signatures40 PART I - FINANCIAL INFORMATION Preferred stock, $0.0001 par value; 10,000,000 shares authorized; Series C Convertible PreferredStock, 3,077 and 3,800 shares issued and outstanding at March 31, 2026 and December 31, 2025,respectively;Liquidation preference $3.077 million at March 31, 2026 Series D Convertible Preferred Stock,5,000 shares issued and outstanding at March 31, 2026 and December 31, 2025;3,067,0003,790,000Liquidation preference $5 million at March 31, 20268,837,5278,837,527Series E Convertible Preferred Stock, 19,500 shares issued and outstanding at March 31, 2026and December 31, 2025; Liquidation preference $19.5 million at March 31, 202614,916,75314,916,753Common stock, $0.0001 par value; 100,000,000 shares authorized; 8,327,076 shares issued and8,323,609 shares outstanding at March 31, 2026; 4,857,476 shares issued and 4,854,009 sharesoutstanding at December 31, 2025832486Additional paid-in capital96,073,37688,376,767Less: common stock held in treasury, at cost; 3,467 shares at March 31, 2026 and December 31,2025(522,500)(522,500)Accumulated deficit(110,413,796)(105,934,101)Statutory reserve6,5786,578Accumulated other comprehensive loss(241,713)(241,402)Total Avalon GloboCare Corp. stockholders’ equity11,724,0579,230,108Noncontrolling interest--Total Equity11,724,0579,230,108Total Liabilities and Equity$ 16,245,467$ 23,400,737See accompanying notes to the condensed consolidated financial statements.-1- AVALON GLOBOCARE CORP. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited) COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP.